These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1069 related articles for article (PubMed ID: 15116347)

  • 1. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.
    Sweeting MJ; Sutton AJ; Lambert PC
    Stat Med; 2004 May; 23(9):1351-75. PubMed ID: 15116347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.
    Bradburn MJ; Deeks JJ; Berlin JA; Russell Localio A
    Stat Med; 2007 Jan; 26(1):53-77. PubMed ID: 16596572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of methods to detect publication bias in meta-analysis.
    Macaskill P; Walter SD; Irwig L
    Stat Med; 2001 Feb; 20(4):641-54. PubMed ID: 11223905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data.
    Stijnen T; Hamza TH; Ozdemir P
    Stat Med; 2010 Dec; 29(29):3046-67. PubMed ID: 20827667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimators and confidence intervals for the marginal odds ratio using logistic regression and propensity score stratification.
    Stampf S; Graf E; Schmoor C; Schumacher M
    Stat Med; 2010 Mar; 29(7-8):760-9. PubMed ID: 20213703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of underlying risk as a source of heterogeneity in meta-analyses: a simulation study of Bayesian and frequentist implementations of three models.
    Dohoo I; Stryhn H; Sanchez J
    Prev Vet Med; 2007 Sep; 81(1-3):38-55. PubMed ID: 17477995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical methods for meta-analyses including information from studies without any events-add nothing to nothing and succeed nevertheless.
    Kuss O
    Stat Med; 2015 Mar; 34(7):1097-116. PubMed ID: 25446971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells.
    Rücker G; Schwarzer G; Carpenter J; Olkin I
    Stat Med; 2009 Feb; 28(5):721-38. PubMed ID: 19072749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research.
    Sterne JA; Jüni P; Schulz KF; Altman DG; Bartlett C; Egger M
    Stat Med; 2002 Jun; 21(11):1513-24. PubMed ID: 12111917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials.
    Lathyris DN; Trikalinos TA; Ioannidis JP
    Int J Epidemiol; 2007 Apr; 36(2):422-30. PubMed ID: 17301102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-fold table cell frequencies imputation in meta analysis.
    Di Pietrantonj C
    Stat Med; 2006 Jul; 25(13):2299-322. PubMed ID: 16025540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal and repeated cross-sectional cluster-randomization designs using mixed effects regression for binary outcomes: bias and coverage of frequentist and Bayesian methods.
    Localio AR; Berlin JA; Have TR
    Stat Med; 2006 Aug; 25(16):2720-36. PubMed ID: 16345043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
    Moya F; Sinha S; Gadzinowski J; D'Agostino R; Segal R; Guardia C; Mazela J; Liu G;
    Pediatrics; 2007 Jun; 119(6):e1361-70. PubMed ID: 17533176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of rare and adverse event data.
    Sutton AJ; Cooper NJ; Lambert PC; Jones DR; Abrams KR; Sweeting MJ
    Expert Rev Pharmacoecon Outcomes Res; 2002 Aug; 2(4):367-79. PubMed ID: 19807443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes.
    Curtin F; Elbourne D; Altman DG
    Stat Med; 2002 Aug; 21(15):2145-59. PubMed ID: 12210630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of binary data: which within study variance estimate to use?
    Chang BH; Waternaux C; Lipsitz S
    Stat Med; 2001 Jul; 20(13):1947-56. PubMed ID: 11427951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application and comparison of meta and pooled analyses in the study of cancer epidemiology].
    Xiang Y; Gao Y; Wang T
    Zhonghua Zhong Liu Za Zhi; 1999 Sep; 21(5):354-8. PubMed ID: 11776573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decade of trials of interferon-alpha for chronic hepatitis C. A meta-regression analysis.
    Tinè F; Attanasio M; Russo F; Pagliaro L
    Contemp Clin Trials; 2005 Apr; 26(2):179-210. PubMed ID: 15837440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs.
    Pogue J; Walter SD; Yusuf S
    Clin Trials; 2009 Jun; 6(3):239-51. PubMed ID: 19528133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.